BAJAJ BROKING
Cipla Ltd. reported a strong financial performance in Q4 FY24-25, posting a 30% year-on-year rise in net profit to Rs.1,222 crore, compared to Rs.939 crore in the same quarter last year. Revenue from operations stood at Rs.6,597.72 crore, marking an 8.45% increase from Rs.6,082.37 crore in Q4 FY24.
Revenue: Rs.6,597.72 crore, up 8.45% YoY from Rs.6,082.37 crore
Net Profit: Rs.1,222 crore, up 30% YoY from Rs.939 crore
EBITDA: Rs.1,537 crore, up 16.8% YoY from Rs.1,316 crore
Total Dividend: Rs.16 per share (Final: Rs.13 + Special: Rs.3)
Cipla closed the financial year with a strong Q4 showing, delivering healthy gains in profitability and topline growth. The 30% rise in net profit was driven by solid operational performance and improved EBITDA, which rose to Rs.1,537 crore. Revenue growth was supported by continued demand across key markets and an expanding portfolio.
The company's board declared a total dividend of Rs.16 per share, including a Rs.3 special dividend. The record date has been set for 27 June 2025, with the payout scheduled within 30 days of the annual general meeting.
Cipla’s core pharmaceuticals segment generated Rs.6,503.63 crore in Q4 FY25, rising from Rs.5,996.38 crore in the year-ago period. Revenue from new ventures stood at Rs.288.48 crore, reflecting a strong 35.4% YoY growth from Rs.212.99 crore.
This balanced growth across legacy operations and emerging segments highlights Cipla’s multi-channel revenue approach, ensuring long-term scalability and margin expansion.
The pharma industry projected moderate earnings growth in Q4 FY25. Cipla outperformed sector averages, particularly in profitability, backed by efficient cost controls and segment expansion. The strong dividend payout further underlines the company’s confidence in future earnings stability and shareholder returns.
Metric | Q4 FY24-25 | Q4 FY23-24 | YoY Change (%) |
Revenue from Operations | Rs.6,597.72 crore | Rs.6,082.37 crore | +8.45% |
EBITDA | Rs.1,537 crore | Rs.1,316 crore | +16.8% |
Net Profit (PAT) | Rs.1,222 crore | Rs.939 crore | +30.1% |
Pharma Segment Revenue | Rs.6,503.63 crore | Rs.5,996.38 crore | +8.47% |
New Ventures Revenue | Rs.288.48 crore | Rs.212.99 crore | +35.4% |
Dividend (Total) | Rs.16 per share | – | – |
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Source: Cipla Ltd – Board Meeting Outcome and Audited Q4 FY25 Financial Results
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading